975 related articles for article (PubMed ID: 27358174)
1. Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives.
Arab JP; Karpen SJ; Dawson PA; Arrese M; Trauner M
Hepatology; 2017 Jan; 65(1):350-362. PubMed ID: 27358174
[TBL] [Abstract][Full Text] [Related]
2. The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
Chow MD; Lee YH; Guo GL
Mol Aspects Med; 2017 Aug; 56():34-44. PubMed ID: 28442273
[TBL] [Abstract][Full Text] [Related]
3. Bile Acids in Nonalcoholic Fatty Liver Disease: New Concepts and therapeutic advances.
Cruz-Ramón V; Chinchilla-López P; Ramírez-Pérez O; Méndez-Sánchez N
Ann Hepatol; 2017 Nov; 16(Suppl. 1: s3-105.):s58-s67. PubMed ID: 29080343
[TBL] [Abstract][Full Text] [Related]
4. Bile acid and nonalcoholic steatohepatitis: Molecular insights and therapeutic targets.
Cheng Z; Chen Y; Schnabl B; Chu H; Yang L
J Adv Res; 2024 May; 59():173-187. PubMed ID: 37356804
[TBL] [Abstract][Full Text] [Related]
5. Bile acids as regulators of hepatic lipid and glucose metabolism.
Trauner M; Claudel T; Fickert P; Moustafa T; Wagner M
Dig Dis; 2010; 28(1):220-4. PubMed ID: 20460915
[TBL] [Abstract][Full Text] [Related]
6. Bile Acid Control of Metabolism and Inflammation in Obesity, Type 2 Diabetes, Dyslipidemia, and Nonalcoholic Fatty Liver Disease.
Chávez-Talavera O; Tailleux A; Lefebvre P; Staels B
Gastroenterology; 2017 May; 152(7):1679-1694.e3. PubMed ID: 28214524
[TBL] [Abstract][Full Text] [Related]
7. Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH).
Fiorucci S; Biagioli M; Sepe V; Zampella A; Distrutti E
Expert Opin Investig Drugs; 2020 Jun; 29(6):623-632. PubMed ID: 32552182
[TBL] [Abstract][Full Text] [Related]
8. Role of FXR in Bile Acid and Metabolic Homeostasis in NASH: Pathogenetic Concepts and Therapeutic Opportunities.
Radun R; Trauner M
Semin Liver Dis; 2021 Nov; 41(4):461-475. PubMed ID: 34289507
[TBL] [Abstract][Full Text] [Related]
9. Interaction of gut microbiota with dysregulation of bile acids in the pathogenesis of nonalcoholic fatty liver disease and potential therapeutic implications of probiotics.
Chen J; Thomsen M; Vitetta L
J Cell Biochem; 2019 Mar; 120(3):2713-2720. PubMed ID: 30443932
[TBL] [Abstract][Full Text] [Related]
10. Recent insights into farnesoid X receptor in non-alcoholic fatty liver disease.
Xu JY; Li ZP; Zhang L; Ji G
World J Gastroenterol; 2014 Oct; 20(37):13493-500. PubMed ID: 25309079
[TBL] [Abstract][Full Text] [Related]
11. Bile acid and receptors: biology and drug discovery for nonalcoholic fatty liver disease.
Jiao TY; Ma YD; Guo XZ; Ye YF; Xie C
Acta Pharmacol Sin; 2022 May; 43(5):1103-1119. PubMed ID: 35217817
[TBL] [Abstract][Full Text] [Related]
12. Bile Acid Receptors and the Gut-Liver Axis in Nonalcoholic Fatty Liver Disease.
Xue R; Su L; Lai S; Wang Y; Zhao D; Fan J; Chen W; Hylemon PB; Zhou H
Cells; 2021 Oct; 10(11):. PubMed ID: 34831031
[TBL] [Abstract][Full Text] [Related]
13. Bile acids and insulin resistance: implications for treating nonalcoholic fatty liver disease.
Wei J; Qiu DK; Ma X
J Dig Dis; 2009 May; 10(2):85-90. PubMed ID: 19426389
[TBL] [Abstract][Full Text] [Related]
14. Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease.
Arab JP; Arrese M; Trauner M
Annu Rev Pathol; 2018 Jan; 13():321-350. PubMed ID: 29414249
[TBL] [Abstract][Full Text] [Related]
15. Bile acid receptors and nonalcoholic fatty liver disease.
Yuan L; Bambha K
World J Hepatol; 2015 Dec; 7(28):2811-8. PubMed ID: 26668692
[TBL] [Abstract][Full Text] [Related]
16. Bile acid sequestration reverses liver injury and prevents progression of nonalcoholic steatohepatitis in Western diet-fed mice.
Takahashi S; Luo Y; Ranjit S; Xie C; Libby AE; Orlicky DJ; Dvornikov A; Wang XX; Myakala K; Jones BA; Bhasin K; Wang D; McManaman JL; Krausz KW; Gratton E; Ir D; Robertson CE; Frank DN; Gonzalez FJ; Levi M
J Biol Chem; 2020 Apr; 295(14):4733-4747. PubMed ID: 32075905
[TBL] [Abstract][Full Text] [Related]
17. Farnesoid X receptor agonist INT-767 attenuates liver steatosis and inflammation in rat model of nonalcoholic steatohepatitis.
Hu YB; Liu XY; Zhan W
Drug Des Devel Ther; 2018; 12():2213-2221. PubMed ID: 30038487
[TBL] [Abstract][Full Text] [Related]
18. Bile acid receptors in non-alcoholic fatty liver disease.
Li Y; Jadhav K; Zhang Y
Biochem Pharmacol; 2013 Dec; 86(11):1517-24. PubMed ID: 23988487
[TBL] [Abstract][Full Text] [Related]
19. Pharmacologic Modulation of Bile Acid-FXR-FGF15/FGF19 Pathway for the Treatment of Nonalcoholic Steatohepatitis.
Schumacher JD; Guo GL
Handb Exp Pharmacol; 2019; 256():325-357. PubMed ID: 31201553
[TBL] [Abstract][Full Text] [Related]
20. The role of fibroblast growth factor 19 in the pathogenesis of nonalcoholic fatty liver disease.
Chrysavgis L; Giannakodimos I; Chatzigeorgiou A; Tziomalos K; Papatheodoridis G; Cholongitas E
Expert Rev Gastroenterol Hepatol; 2022 Sep; 16(9):835-849. PubMed ID: 36124827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
